| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 12.8 | 9.0 | 12.9 |
| Other income | 0.1 | 0.5 | 0.1 |
| Total income | 12.9 | 9.5 | 13.0 |
| Profit before exceptional items & tax | 1.6 | -0.1 | 1.8 |
| Profit before tax | 1.6 | -0.1 | 1.8 |
| Net profit | 1.3 | -0.2 | 1.4 |
| Operating margin | 12.4% | -1.1% | 13.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -7.10% |
|---|---|
| Revenue, year on year | -0.80% |
| Operating profit, year on year | -11.80% |
| Operating profit, quarter on quarter | +350.00% |
BSE results filing, NSE: GUJTERC. Figures extracted from the filing.
Gujarat Terce Laboratories Ltd: key numbers
- Share price
- ₹47.00
- Market cap
- ₹34.88 Cr
- Revenue (annual)
- ₹47.47 Cr
- Net profit (annual)
- ₹2.20 Cr
- P/E (TTM)
- 16.7×Sector 37.9×
- Promoter holding
- 40.03%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Terce Laboratories Ltd
All →Gujarat Terce Laboratories Acquisition Worth ₹3.23 Cr
Gujarat Terce Laboratories agreed to buy its corporate office premises 'Swati18' in Ahmedabad. The purchase is for Rs 3.23 Crore, excluding taxes and charges.
- Value
- ₹3.23 Cr
Gujarat Terce Laboratories Board Meeting Date
Gujarat Terce Laboratories will hold a board meeting on November 5, 2026 to consider unaudited standalone results for September 2026. The trading window stays closed until November 7, 2026.
Gujarat Terce Laboratories Other Announcement
Gujarat Terce Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Gujarat Terce Laboratories Annual General Meeting
Gujarat Terce Laboratories held its 41st Annual General Meeting on August 21, 2026. Members passed resolutions regarding financial statements and director re-appointments.
Gujarat Terce Laboratories Management Change
Gujarat Terce Laboratories issued a corrigendum clarifying the re-appointment tenure of its MD & CEO, Mr. Aalap Prajapati, as three years instead of five.
Gujarat Terce Laboratories Q1 FY27 Results: Net Loss of ₹0.2 Cr
Gujarat Terce Laboratories Ltd reported revenue from operations of ₹9 Cr (-17.4% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.2 Cr